Home » Celegne’s Revlimid Granted Marketing Authorization in Japan
Celegne’s Revlimid Granted Marketing Authorization in Japan
Pharmaceutical company Celgene International said that Revlimid (lenalidomide) has been granted full marketing authorization by Japan’s Ministry of Health, Labour and Welfare for the treatment of patients with myelodysplastic syndromes associated with a deletion 5q cytogenic abnormality.
TradingMarkets
TradingMarkets
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May